Hemolytic Uremic Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hemolytic Uremic Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Hemolytic uremic syndrome (HUS) is a rare but serious condition that affects the blood vessels and kidneys. It is caused by the damage and inflammation of small blood vessels, which leads to the formation of blood clots that block the flow of blood and oxygen to the organs. HUS can result in anemia, low platelet count, and kidney failure.
The most common cause of HUS is infection with certain strains of Escherichia coli (E. coli) bacteria that produce a toxin called Shiga toxin. These bacteria are usually found in contaminated food or water, especially undercooked meat, unpasteurized milk, or raw fruits and vegetables. Other causes of HUS include other infections, certain medications, pregnancy, cancer, or autoimmune diseases. Most people recover from HUS with proper treatment, but some may have long-term kidney problems or other complications.
The Hemolytic Uremic Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Hemolytic Uremic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemolytic Uremic Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hemolytic Uremic Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 25 molecules, with 25 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hemolytic Uremic Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hemolytic Uremic Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hemolytic Uremic Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adienne Pharma & Biotech SAAevitas Therapeutics Inc
AffaMed Therapeutics US Inc
Alexion Pharmaceuticals Inc
Amgen Inc
Eleva GmbH
Eligo Bioscience SA
F. Hoffmann-La Roche Ltd
ImmunAbs Inc
Inmunova SA
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Prestige BioPharma Ltd
Tasly Biopharmaceuticals Co Ltd
Turgut Ilaclari AS
UCB SA
Zhuhai Trinomab Biotechnology Co Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hemolytic Uremic Syndrome reports